Several healthcare stocks have consensus price targets suggesting that their shares may more than double in the coming quarters.
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise. However, looking to Wall Street analyst ratings and predictions can be a helpful place to start.
This drug has also shown promise in clinical trials for the treatment of certain other types of melanoma. This has led to KIMMTRAK revenues of more than $80 million in the latest quarter, 28% higher than one year earlier. Analysts expect KIMMTRAK to reach the broader market by 2027. All told, analysts believe GH's shares could more than quadruple in price to $36.67. It's important to note, though, that this is based on just three ratings.Intellia is a genome editing company that uses engineered cell therapies, among other things, to develop treatments for cancers and autoimmune diseases. The company recently reported strong trial enrollment and demand for its multiple leading therapeutic candidates.
During this quarter, the company also made significant progress toward approval of its in vivo gene editing technology nex-z. Analysts believe shares of NTLA could rise by more than 250%, based on a consensus price target of $58.13.Each of these three firms is preparing potentially transformative therapeutic products or technology for market launch.
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
स्रोत: Investingcom - 🏆 450. / 53 और पढो »
स्रोत: Investingcom - 🏆 450. / 53 और पढो »